220 related articles for article (PubMed ID: 37936688)
1. Structure and functions of Mer, an innate immune checkpoint.
Ubil E; Zahid KR
Front Immunol; 2023; 14():1244170. PubMed ID: 37936688
[TBL] [Abstract][Full Text] [Related]
2. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.
Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
Pharmacol Ther; 2020 Sep; 213():107577. PubMed ID: 32417270
[TBL] [Abstract][Full Text] [Related]
3. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
4. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.
Akalu YT; Rothlin CV; Ghosh S
Immunol Rev; 2017 Mar; 276(1):165-177. PubMed ID: 28258690
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
6. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
7. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.
Mohd Idrus FN; Ahmad NS; Hoe CH; Azlan M; Norfuad FA; Yusof Z; Wan Isa WYH; Mohamed Ali AA; Yvonne-Tee GB
BMC Immunol; 2021 Mar; 22(1):21. PubMed ID: 33761885
[TBL] [Abstract][Full Text] [Related]
8. Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease.
Miller MA; Kim E; Cuccarese MF; Plotkin AL; Prytyskach M; Kohler RH; Pittet MJ; Weissleder R
Chem Commun (Camb); 2017 Dec; 54(1):42-45. PubMed ID: 29185561
[TBL] [Abstract][Full Text] [Related]
9. Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.
Zizzo G; Cohen PL
Inflammation; 2018 Dec; 41(6):2206-2221. PubMed ID: 30091033
[TBL] [Abstract][Full Text] [Related]
10. Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
[TBL] [Abstract][Full Text] [Related]
11. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.
Bernsmeier C; Pop OT; Singanayagam A; Triantafyllou E; Patel VC; Weston CJ; Curbishley S; Sadiq F; Vergis N; Khamri W; Bernal W; Auzinger G; Heneghan M; Ma Y; Jassem W; Heaton ND; Adams DH; Quaglia A; Thursz MR; Wendon J; Antoniades CG
Gastroenterology; 2015 Mar; 148(3):603-615.e14. PubMed ID: 25479139
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
[TBL] [Abstract][Full Text] [Related]
13. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
[TBL] [Abstract][Full Text] [Related]
15. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
[TBL] [Abstract][Full Text] [Related]
16. Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury.
Wu H; Zheng J; Xu S; Fang Y; Wu Y; Zeng J; Shao A; Shi L; Lu J; Mei S; Wang X; Guo X; Wang Y; Zhao Z; Zhang J
J Neuroinflammation; 2021 Jan; 18(1):2. PubMed ID: 33402181
[TBL] [Abstract][Full Text] [Related]
17. MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury.
DeBerge M; Yeap XY; Dehn S; Zhang S; Grigoryeva L; Misener S; Procissi D; Zhou X; Lee DC; Muller WA; Luo X; Rothlin C; Tabas I; Thorp EB
Circ Res; 2017 Sep; 121(8):930-940. PubMed ID: 28851810
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
19. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction.
Zizzo G; Hilliard BA; Monestier M; Cohen PL
J Immunol; 2012 Oct; 189(7):3508-20. PubMed ID: 22942426
[TBL] [Abstract][Full Text] [Related]
20. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
